Abstract
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are increasing in incidence. They are a highly diverse family of neoplasms that can be categorized based on multiple factors including tumor differentiation, grade, stage, site of origin, hormonal output, rate of growth, and somatostatin receptor expression. Treatment options vary significantly based on each of the above-mentioned factors. Systemic therapies for patients with metastatic well-differentiated NETs have expanded significantly in recent years to include inhibitors of the mammalian target of Rapamycin (mTOR) enzyme, peripheral serotonin inhibitors, and radiolabeled somatostatin analogs. This chapter highlights clinical presentations, radiographic findings, genetic landscape, locoregional treatment options, and systemic treatments for patients with advanced GEP-NETs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Sleisenger and Fordtran's Gastrointestinal and Liver Disease
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
